FDA Delivers Latest CBD Study to Congress

On July 8, 2020, the U.S. Food and Drug Administration (“FDA”) delivered the results of its most comprehensive sampling study on the current cannabidiol (“CBD”) marketplace to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations.1 Congress mandated FDA to … Read more about FDA Delivers Latest CBD Study to Congress

FDA Proposes $5 Million Budget to Regulate CBD in 2021

President Trump’s budget proposal for the 2021 fiscal year, which is set to be presented to Congress next year, should he gain re-election, includes $6.2 billion in overall funding for the Food and Drug Administration (“FDA”). This proposal includes a $5 million-line item for FDA to continue … Read more about FDA Proposes $5 Million Budget to Regulate CBD in 2021

Panel on CBD Marketing and Labeling Rules

Firm founder and Managing Partner Dave Rodman was a panelist at the CBDIA expo in October 2019. The focus of the panel was on Marketing and Labeling issues for CBD products from an FDA standpoint. It was so popular that ValidCare hosted a follow up webinar on the same topic with the same panelists … Read more about Panel on CBD Marketing and Labeling Rules